| Project/Area Number |
26461773
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Psychiatric science
|
|---|
| Research Institution | Juntendo University |
|---|
Principal Investigator |
Hatta Kotaro 順天堂大学, 医学部, 教授 (90337915)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
岸 泰宏 日本医科大学, 医学部, 准教授 (60256930)
竹内 崇 東京医科歯科大学, 医学部附属病院, 講師 (70345289)
小田原 俊成 横浜市立大学, 保健管理センター, 教授 (00244426)
杉田 学 順天堂大学, 医学部, 先任准教授 (20322414)
町田 裕 順天堂大学, 医学部, 非常勤講師 (90317470)
野田 隆政 国立研究開発法人国立精神・神経医療研究センター, 病院, 医長 (50446572)
臼井 千恵 順天堂大学, 医学部, 准教授 (70453587)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | スボレキサント / せん妄 / 予防 / 臨床試験 / オレキシン / ランダム化試験 / delirium / suvorexant / prevention / clinical trial / 予測 / S100β / インスリン様成長因子Ⅰ / C反応蛋白 / 高感度C反応蛋白 |
|---|
| Outline of Final Research Achievements |
We examined whether suvorexant, a potent and selective orexin receptor antagonist, is effective for the prevention of delirium.Method: We conducted a multi-center, rater-blinded, randomized placebo-controlled clinical trial in intensive care units and regular acute wards between April 2015 and March 2016. Eligible patients were 65-89 years old and newly admitted due to emergency. Seventy-two patients were randomly assigned to receive suvorexant (15 mg/day; 36 patients) and placebo (36 patients) every night for three days. The primary outcome measure was incidence of delirium as determined by the DSM-5. Trained psychiatrists assessed for delirium. We found that development of delirium occurred significantly less often among patients taking suvorexant than those taking placebo (0% [n/N=0/36] vs. 17% [6/36], P=.025). Suvorexant administered nightly to elderly patients admitted for acute care may provide protection against delirium.
|
